BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

448 related articles for article (PubMed ID: 31724047)

  • 21. The Role of Iron and Siderophores in Infection, and the Development of Siderophore Antibiotics.
    Page MGP
    Clin Infect Dis; 2019 Nov; 69(Suppl 7):S529-S537. PubMed ID: 31724044
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In Vitro Activity of Cefiderocol Against a Broad Range of Clinically Important Gram-negative Bacteria.
    Yamano Y
    Clin Infect Dis; 2019 Nov; 69(Suppl 7):S544-S551. PubMed ID: 31724049
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, Against Gram-Negative Bacilli Isolated by Clinical Laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015.
    Karlowsky JA; Hackel MA; Tsuji M; Yamano Y; Echols R; Sahm DF
    Int J Antimicrob Agents; 2019 Apr; 53(4):456-466. PubMed ID: 30471402
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activity of the novel siderophore cephalosporin cefiderocol against multidrug-resistant Gram-negative pathogens.
    Dobias J; Dénervaud-Tendon V; Poirel L; Nordmann P
    Eur J Clin Microbiol Infect Dis; 2017 Dec; 36(12):2319-2327. PubMed ID: 28748397
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antimicrobial Activity of Cefiderocol against the Carbapenemase-Producing Enterobacter cloacae Complex and Characterization of Reduced Susceptibility Associated with Metallo-β-Lactamase VIM-1.
    Lasarte-Monterrubio C; Guijarro-Sánchez P; Vázquez-Ucha JC; Alonso-Garcia I; Alvarez-Fraga L; Outeda M; Martinez-Guitian M; Peña-Escolano A; Maceiras R; Lence E; González-Bello C; Arca-Suárez J; Bou G; Beceiro A
    Antimicrob Agents Chemother; 2023 May; 67(5):e0150522. PubMed ID: 37195077
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Siderophore Cephalosporin Cefiderocol Utilizes Ferric Iron Transporter Systems for Antibacterial Activity against Pseudomonas aeruginosa.
    Ito A; Nishikawa T; Matsumoto S; Yoshizawa H; Sato T; Nakamura R; Tsuji M; Yamano Y
    Antimicrob Agents Chemother; 2016 Dec; 60(12):7396-7401. PubMed ID: 27736756
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cefiderocol, a Siderophore Cephalosporin, as a Treatment Option for Infections Caused by Carbapenem-Resistant Enterobacterales.
    Kaye KS; Naas T; Pogue JM; Rossolini GM
    Infect Dis Ther; 2023 Mar; 12(3):777-806. PubMed ID: 36847998
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacological and clinical profile of cefiderocol, a siderophore cephalosporin against gram-negative pathogens.
    Jorda A; Zeitlinger M
    Expert Rev Clin Pharmacol; 2021 Jul; 14(7):777-791. PubMed ID: 33849355
    [No Abstract]   [Full Text] [Related]  

  • 29. High efficacy and enhanced synergistic activity of the novel siderophore-cephalosporin cefiderocol against multidrug-resistant and extensively drug-resistant Klebsiella pneumoniae from inpatients attending a single hospital in the United Arab Emirates.
    Daoud L; Al-Marzooq F; Ghazawi A; Anes F; Collyns T
    J Infect Public Health; 2023 Dec; 16 Suppl 1():33-44. PubMed ID: 37953111
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stability and low induction propensity of cefiderocol against chromosomal AmpC β-lactamases of Pseudomonas aeruginosa and Enterobacter cloacae.
    Ito A; Nishikawa T; Ota M; Ito-Horiyama T; Ishibashi N; Sato T; Tsuji M; Yamano Y
    J Antimicrob Chemother; 2018 Nov; 73(11):3049-3052. PubMed ID: 30188999
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of Humanized Exposures of Cefiderocol (S-649266) against a Diverse Population of Gram-Negative Bacteria in a Murine Thigh Infection Model.
    Monogue ML; Tsuji M; Yamano Y; Echols R; Nicolau DP
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28848004
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ARGONAUT-I: Activity of Cefiderocol (S-649266), a Siderophore Cephalosporin, against Gram-Negative Bacteria, Including Carbapenem-Resistant Nonfermenters and
    Jacobs MR; Abdelhamed AM; Good CE; Rhoads DD; Hujer KM; Hujer AM; Domitrovic TN; Rudin SD; Richter SS; van Duin D; Kreiswirth BN; Greco C; Fouts DE; Bonomo RA
    Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30323050
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cefiderocol Antimicrobial Susceptibility Testing Considerations: the Achilles' Heel of the Trojan Horse?
    Simner PJ; Patel R
    J Clin Microbiol; 2020 Dec; 59(1):. PubMed ID: 32727829
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In Vitro Activity of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacilli Isolated from Patients in Canadian Intensive Care Units.
    Golden AR; Adam HJ; Baxter M; Walkty A; Lagacé-Wiens P; Karlowsky JA; Zhanel GG
    Diagn Microbiol Infect Dis; 2020 May; 97(1):115012. PubMed ID: 32081522
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genomic Modification of TonB and Emergence of Small-Colony Phenotype in VIM- and NDM-Producing Escherichia coli following Cefiderocol Exposure
    Kocer K; Boudour-Halil D; Chanthalangsy Q; Sähr A; Heeg K; Boutin S; Nurjadi D
    Antimicrob Agents Chemother; 2023 May; 67(5):e0011823. PubMed ID: 37022155
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cefiderocol: A Review in Serious Gram-Negative Bacterial Infections.
    Syed YY
    Drugs; 2021 Sep; 81(13):1559-1571. PubMed ID: 34427896
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cefiderocol: a novel siderophore cephalosporin for multidrug-resistant Gram-negative bacterial infections.
    Parsels KA; Mastro KA; Steele JM; Thomas SJ; Kufel WD
    J Antimicrob Chemother; 2021 May; 76(6):1379-1391. PubMed ID: 33532823
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prospective role of cefiderocol in the management of carbapenem-resistant Acinetobacter baumannii infections: Review of the evidence.
    Kollef M; Dupont H; Greenberg DE; Viale P; Echols R; Yamano Y; Nicolau DP
    Int J Antimicrob Agents; 2023 Aug; 62(2):106882. PubMed ID: 37301312
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro antimicrobial activity of S-649266, a catechol-substituted siderophore cephalosporin, when tested against non-fermenting Gram-negative bacteria.
    Ito A; Kohira N; Bouchillon SK; West J; Rittenhouse S; Sader HS; Rhomberg PR; Jones RN; Yoshizawa H; Nakamura R; Tsuji M; Yamano Y
    J Antimicrob Chemother; 2016 Mar; 71(3):670-7. PubMed ID: 26645269
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cefiderocol Resistance in Acinetobacter baumannii: Roles of β-Lactamases, Siderophore Receptors, and Penicillin Binding Protein 3.
    Malik S; Kaminski M; Landman D; Quale J
    Antimicrob Agents Chemother; 2020 Oct; 64(11):. PubMed ID: 32868330
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.